Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CT-388
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
October 08, 2024
Lead Product(s) : CT-388
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CT-388
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 29, 2024
Lead Product(s) : CT-388
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : $3,100.0 million
Deal Type : Acquisition
Carmot Therapeutics Announces Completion of Acquisition by Roche
Details : Roche will enhance its portfolio with Carmot’s GLP-1/GIP receptor agonists, including CT-388, CT-996, and CT-868, for metabolic diseases like obesity and diabetes.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : $2,700.0 million
January 29, 2024
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : F. Hoffmann-La Roche
Deal Size : $3,100.0 million
Deal Type : Acquisition
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
Obesity and Diabetes Biotech Carmot Therapeutics Files for IPO
Details : The net proceeds will be used to advance the clinical development of CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, for the treatment of type-2 diabetes and obesity.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
November 17, 2023
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : CT-868
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CT-868 is a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed as an adjunct to insulin for the treatment of people with type 1 diabetes (T1D) with overweight or obesity.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
November 15, 2023
Lead Product(s) : CT-868
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CT-996
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). it was designed to exhibit signaling bias on the GLP-1 receptor, resulting in activation of cAMP.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : CT-996
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CT-868
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of CT-868 in Type 1 Diabetes Mellitus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
October 02, 2023
Lead Product(s) : CT-868
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Deep Track Capital
Deal Size : $150.0 million
Deal Type : Series E Financing
Details : The proceeds will be used to strengthen Carmot's portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis, including CT-388, a dual GLP-1/GIP receptor modulator for obese adults with and withou...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
May 25, 2023
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Deep Track Capital
Deal Size : $150.0 million
Deal Type : Series E Financing
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Study Phase : Phase I
Recipient : Kimia Therapeutics
Deal Size : Undisclosed
Deal Type : Demerger
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease
Details : The spin-off enables Carmot to focus on clinical-stage candidates CT-388 and CT-868 (dual GLP-1/GIP receptor modulators), additional IND-stage programs including CT-996 (an oral, small molecule GLP-1 receptor agonist) and a long-acting PYY analogue.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
May 01, 2023
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Recipient : Kimia Therapeutics
Deal Size : Undisclosed
Deal Type : Demerger
Lead Product(s) : CT-996
Therapeutic Area : Endocrinology
Study Phase : Phase I
Recipient : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2023
Lead Product(s) : CT-996
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Recipient : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable